Idursulfase - JCR Pharmaceuticals

Drug Profile

Idursulfase - JCR Pharmaceuticals

Alternative Names: JR 141; Recombinant iduronate-2-sulfatase - JCR Pharmaceuticals

Latest Information Update: 02 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator JCR Pharmaceuticals
  • Class Iduronate sulfatases
  • Mechanism of Action Iduronate sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis II

Most Recent Events

  • 30 Mar 2017 Phase-I/II clinical trials in Mucopolysaccharidosis II (In adults, In children, In the elderly, Treatment-experienced) in Japan (IV) (NCT03128593)
  • 01 Dec 2016 JCR Pharmaceutical submits phase I/II clinical trial plan with the Pharmaceutical and Medical Devices Agency in Japan for Mucopolysaccharidosis (9215473​)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top